The American Society of Clinical Oncology’s annual meeting is quickly approaching. The 2025 ASCO Annual Meeting (ASCO25) is set for May 30 through June 3, in Chicago, Illinois. The five-day conference features oncology experts from all across the world gathering to share the latest insights, emerging technologies, and connect with colleagues between premiere events.

Registration for the 2025 ASCO Annual Meeting is now open. 

With more than 200 sessions, and even more presentations, we sorted through them all and below you’ll find sessions that feature topics on hematologic malignancies. For a complete look at all the scheduled sessions at ASCO25, view the official program guide.

Hematologic Malignancies — Leukemia, Myelodysplastic Syndromes, and Allotransplant

Friday, May 30, 2025 | 1:00 PM

Presentations:

  • 1:00 PM – A phase I study of asciminib in combination with dasatinib, prednisone, and blinatumomab for Ph-positive acute leukemia in adults.
  • 1:06 PM – MRD negativity after end of induction in the phase 3 PhALLCON trial: A post hoc analysis.
  • 1:12 PM – Reduced dose PTCy in patients with acute myeloid leukemia receiving matched unrelated donor allogeneic hematopoietic stem cell transplantation.
  • 1:18 PM – Q&A Panel
  • 1:30 PM – Overall survival (OS) and duration of response for transfusion independence (TI) in erythropoiesis stimulating agent (ESA)–naive patients (pts) with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) treated with luspatercept (LUSPA) vs epoetin alfa (EA) in the COMMANDS trial.
  • 1:36 PM – Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study.
  • 1:42 PM – Dosing decitabine and venetoclax for terminal differentiation to improve outcomes in TP53 mutant MDS and AML.
  • 1:48 PM – Q&A Panel
  • 2:00 PM – IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF).
  • 2:08 PM – Efficacy and safety of asciminib (ASC) in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI): Interim analysis (IA) of the phase 2 ASC2ESCALATE trial.
  • 2:12 PM – Age-related macular degeneration in individuals with clonal hematopoiesis.
  • 2:18 PM – Q&A Panel

Hematological Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Friday, May 30, 2025 | 2:45 PM

Presentations:

  • 2:45 PM – Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial.
  • 2:57 PM – Revision of staging system for natural killer T-cell lymphoma: A multicenter study from the Chinese Southwest Oncology Group and Asia Lymphoma Study Group.
  • 3:09 PM – Molecular landscape of distinct follicular lymphoma histologic grades: Insights from genomic and transcriptome analyses.
  • 3:21 PM – Moving the Needle: Improving Clinical and Molecular Risk Stratification in Lymphoma
  • 3:33 PM – Panel Q&A
  • 3:45 PM – A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).
  • 3:57 PM – Multi-virus specific T cells to enhance the activity of bispecific antibodies in lymphoma.
  • 4:09 PM – WaveLINE-003: Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma.
  • 4:21 PM – Strengthening the Strike: Novel Treatment Approaches in Relapsed-Refractory Large B-Cell Lymphoma
  • 4:33 PM – Panel Q&A
  • 4:45 PM – Sintilimab (anti-PD-1 antibody) combined with chidamide (an oral subtype-selective HDACi) followed by P-GemOx regimen in patients with treatment-naïve extranodal natural killer/T cell lymphoma (TN-ENKTL): A multicenter, open-label, single-arm, phase II study (SCENT-2 trial).
  • 4:57 PM – Sintilimab (anti-PD-1) plus ifosfamide, carboplatin, and etoposide (ICE) in second-line classical Hodgkin lymphoma (cHL): Results of a multicenter, randomized, controlled, double-blind phase 3 study (ORIENT-21).
  • 5:09 PM – Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203).
  • 5:21 PM – Reinventing Immunotherapy in Hodgkin Lymphoma and Extranodal NK/T-Cell Lymphoma
  • 5:33 PM – Panel Q&A

After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor-Positive Metastatic Breast Cancer

Friday, May 30, 2025 | 4:30 PM

Presentations:

  • 4:30 PM – Optimizing Targeted Therapies and Endocrine Combinations With Molecular Markers
  • 4:42 PM – What’s on the Horizon: Emerging Agents for Second Line and Beyond in Hormone Receptor-Positive Disease
  • 4:54 PM – Weighing Priorities: A Patient Advocate’s Perspective on Individualized Treatment Approaches
  • 5:06 PM – Cytotoxic Therapy in Metastatic Hormone-Receptor Breast Cancer: Antibody-Drug Conjugates and Chemotherapy in Focus
  • 5:18 PM – Panel Q&A

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Saturday, May 31, 2025 | 8:00 AM

Presentations:

  • 8:00 AM – Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL: Results in SEQUOIA arm D.
  • 8:06 AM – Phase 1/2 studies of DZD8586 in CLL/SLL patients after covalent or non-covalent BTK inhibitors and BTK degraders.
  • 8:12 AM – SEQUOIA 5-year follow-up in arm C: Frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
  • 8:18 AM – Panel Q&A
  • 8:30 AM – A phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/refractory non-Hodgkin lymphoma.
  • 8:36 AM – CD79b-targeted antibody-drug conjugate (ADC) SHR-A1912 in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL): Data from a phase 1b/2 study.
  • 8:42 AM – Fixed duration subcutaneous (SC) mosunetuzumab (Mosun) in patients with previously untreated high-tumor burden follicular lymphoma (FL): Interim results from the phase II MorningSun study.
  • 8:48 AM – Panel Q&A
  • 9:00 AM – Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO.
  • 9:06 AM – Worldwide experience of chronic active EBV infection: Retrospective cohort study.
  • 9:12 AM – Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study.
  • 9:18 AM – Panel Q&A

Myeloproliferative Neoplasms and Chronic Myelogenous Leukemia: New Directions in Therapies and Sequencing Oral Agents

Saturday, May 31, 2025 | 1:15 PM

Presentations:

  • 1:15 PM – Novel Janus Kinase Inhibitors in Myeloproliferative Neoplasms
  • 1:30 PM – Which Are the Best Tyrosine Kinase Inhibitors for Newly Diagnosed Chronic Myelogenous Leukemia?
  • 1:45 PM – Is There a Role for Pegylated Interferons in Myeloproliferative Neoplasms in Present Era?
  • 2:00 PM – Panel Q&A

When and How Long to Treat Chronic Lymphocytic Leukemia

Saturday, May 31, 2025 | 3:00 PM

Presentations:

  • 3:00 PM – When to Start Treatment in Newly Diagnosed Chronic Lymphocytic Leukemia?
  • 3:15 PM – Time-Limited Therapy Versus Indefinite Therapy in Chronic Lymphocytic Leukemia
  • 3:30 PM – Is There a Role for Minimal Residual Disease Testing in Chronic Lymphocytic Leukemia?
  • 3:45 PM – Panel Q&A

Is Minimal Residual Disease Testing Helpful in Managing Multiple Myeloma?

Sunday, June 1, 2025 | 8:00 AM

Presentations:

  • 8:00 AM – Hematologist Oncologist Perspective/Physician-Scientist Perspective
  • 8:40 AM – Panel Q&A

Navigating B-Acute Lymphoblastic Leukemia in the Era of Blinatumomab

Sunday, June 1, 2025 | 8:00 AM

Presentations:

  • 8:00 AM – Who Would and Would Not Benefit From Receiving Blinatumomab in Frontline Treatment of B-Cell Acute Lymphoblastic Leukemia
  • 8:15 AM – Barriers to Blinatumomab Administration and Access: How to Overcome Them
  • 8:30 AM – What Comes Next?
  • 8:45 AM – Panel Q&A

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sunday, June 1, 2025 | 9:00 AM
Poster Session

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sunday, June 1, 2025 | 9:00 AM
Poster Session

Hematologic Malignancies—Plasma Cell Dyscrasia
Sunday, June 1, 2025 | 9:00 AM
Poster Session

Toxicities of Immunotherapies Including CAR T-Cell Therapy

Sunday, June 1, 2025 | 4:30 PM

Presentations:

  • 4:30 PM – Early Complications of Immunotherapies
  • 4:45 PM – Late Complications of Immunotherapies
  • 5:00 PM – Rare Complications of Immunotherapies (Including Secondary Malignancies)
  • 5:15 PM – Panel Question and Answer

Hematologic Malignancies—Plasma Cell Dyscrasia

Sunday, June 2, 2025 | 8:00 AM

Presentations:

  • 8:00 AM – Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) for high-risk (HR) newly diagnosed multiple myeloma (NDMM): First-time report of the full cohort of transplant-eligible (TE) patients in the GMMG-CONCEPT trial.
  • 8:06 AM – Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial.
  • 8:12 AM – Heterogeneity in the expression of GPRC5D between patients with multiple myeloma.
  • 8:18 AM – Panel Q&A
  • 8:30 AM – Belantamab mafodotin plus lenalidomide/dexamethasone in newly diagnosed intermediate-fit & frail multiple myeloma patients: Long-term efficacy and safety from the phase 1/2 BELARD clinical trial.
  • 8:36 AM – Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.
  • 8:42 AM – Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results.
  • 8:48 AM – Panel Q&A
  • 9:00 AM – Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial.
  • 9:06 AM – Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study.
  • 9:12 AM – Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the phase 3 IMROZ study.
  • 9:18 AM – Panel Q&A

New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes

Monday, June 2, 2025 | 9:45 AM

Presentations:

  • 9:45 AM – Which Novel Treatment Should I Use in Low- and Intermediate-Risk Myelodysplastic Syndromes?
  • 10:00 AM – Role of Molecular Testing in Low- and Intermediate-Risk Myelodysplastic Syndromes
  • 10:15 AM – How Do IPSS-R and IPSS-M Affect Treatment Decisions?
  • 10:30 AM – Panel Question and Answer

Changes in Upfront Therapy in Hematologic Malignancies

Monday, June 2, 2025 | 11:30 AM

Presentations:

  • 11:30 AM – Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia?
  • 11:45 AM – Treatment Options for Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
  • 12:00 PM – Should Bispecifics or CART Be Included in Upfront Lymphoma Therapy?
  • 12:15 PM – Panel Q&A

Bispecific and Multispecific Antibodies in Hemato-Oncology

Monday, June 2, 2025 | 11:30 AM

Presentations:

  • 11:30 AM – Bispecific Antibodies for Dual Receptor Inhibition
  • 11:45 AM – Bispecific Antibodies for Cancer Immunotherapy
  • 12:00 PM – Bispecifics Plus Tyrosine Kinase Inhibition in Combination Strategy
  • 12:15 PM – Panel Q&A

Precursors of Hematologic Malignancies: When to Watch and When to Treat

Monday, June 2, 2025 | 1:15 PM

Presentations: 

  • 1:15 PM – Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
  • 1:30 PM – Clonal Hematopoiesis of Indeterminate Potential to Acute Myeloid Leukemia
  • 1:45 PM – Monoclonal B-Cell Lymphocytosis to Chronic Lymphocytic Leukemia
  • 2:00 PM – Panel Q&A

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Monday, June 2, 2025 | 3:00 PM

Presentations:

  • 3:00 PM – Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial
  • 3:12 PM – Primary endpoint results of the phase 3b ASC4START trial of asciminib (ASC) vs nilotinib (NIL) in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP): Time to treatment discontinuation due to adverse events (TTDAE)
  • 3:24 PM – Efficacy and safety of pivekimab sunirine (PVEK) in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA study
  • 3:36 PM – Advancing Hope: Novel Treatments for Myeloproliferative Neoplasms and Blastic Plasmacytoid Dendritic Cell Neoplasm
  • 3:48 PM – Panel Q&A
  • 4:00 PM – Phase II study of cladribine, low-dose cytarabine, and venetoclax, alternating with azacitidine and venetoclax, in higher-risk chronic myelomonocytic leukemia and myelodysplastic syndromes
  • 4:12 PM – An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts
  • 4:24 PM – Phase 1b/2 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients (pts) with treatment-naïve (TN) or prior venetoclax (VEN)-exposed myeloid malignancies
  • 4:36 PM – Ziftomenib in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study
  • 4:48 PM – Shaping the Future of Acute Myeloid Leukemia and Myelodysplastic Syndromes Therap
  • 5:00 PM – Panel Q&A
  • 5:12 PM – γ9δ2 T-cell activation (γδTCA) with ICT01 combined with azacitidine-venetoclax (AV) for older/unfit adults with newly diagnosed (ND) AML: Preliminary efficacy and dose selection in phase 1/2 study EVICTION
  • 5:24 PM – Long-term outcomes of patients surviving beyond 2 years post–allogeneic stem cell transplantation
  • 5:36 PM – Immuno- and Cellular Therapy: New and Old
  • 5:48 PM – Panel Q&A

Current and Future Directions in Immunotherapies in Myeloma

Tuesday, June 3, 2025 | 8:00 AM

Presentations:

  • 8:00 AM – Is There Still a Role for Transplant in Myeloma?
  • 8:15 AM – What Is the Current State of Induction With Four-Drug Therapy?
  • 8:30 AM – Is It Time to Include Bispecifics Into Upfront Therapy?
  • 8:45 AM – Panel Q&A

Hematologic Malignancies—Plasma Cell Dyscrasia

Tuesday, June 3, 2025 | 9:45 AM

Presentations:

  • 9:45 AM – MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial
  • 9:57 AM – Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial
  • 10:09 AM – Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial)
  • 10:21 AM – Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial
  • 10:33 AM – Does the Road to Cure Myeloma End with Minimal Residual Disease?
  • 10:45 AM – Panel Q&A
  • 10:57 AM – Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1
  • 11:09 AM – First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results
  • 11:21 AM – Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study
  • 11:33 AM – New Roads in Myeloma
  • 11:45 AM – Panel Q&A
  • 11:57 AM – Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM)
  • 12:09 PM – Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201
  • 12:21 PM – BCMA- CART, One Treatment, Two Diseases
  • 12:33 PM – Panel Q&A

This schedule is accurate as of May 8, 2025. Adjustments may be made. Consult the official schedule on the ASCO website for the most up-to-date information.

Sign up for alerts and stay informed on the latest published guidelines and conference previews.

Copyright © 2025 Guideline Central, all rights reserved.